Featured Research

from universities, journals, and other organizations

Ethics experts call for refocus of scientific review to ensure integrity of research process

Date:
May 17, 2010
Source:
Carnegie Mellon University
Summary:
In a paper published this week in the journal Science, experts caution that important ethical issues in the testing of new therapies like stem cells may not be receiving the attention they deserve. The authors examine the way scientists, physicians, and regulators evaluate risk and benefit when testing new drugs in human beings for the first time.

In a paper published this week in the journal Science, experts caution that important ethical issues in the testing of new therapies like stem cells may not be receiving the attention they deserve.

Related Articles


Carnegie Mellon University's Alex John London joined McGill University's Jonathan Kimmelman and Marina Emborg of the Wisconsin National Primate Research Center at the University of Wisconsin-Madison to examine the way scientists, physicians, and regulators evaluate risk and benefit when testing new drugs in human beings for the first time. According to their report, scientists and regulators tend to focus on how individual patients should be protected from risks, and as a result, overlook how medical advance itself can be adversely affected by poorly designed clinical trials.

For the past few decades, numerous highly innovative therapies have been introduced into human testing, including genetic-based approaches, stem cells and therapies aimed at reprogramming the immune system. Patients with serious illnesses often flock to these studies in hope of a cure. These studies are often controversial, however, because some scientists and regulators consider them too risky while others suggest it is unethical to deny critically ill patients access to these studies.

London and his co-authors argue that debates over access neglect key ethical issues. "Right now, ethical oversight is highly focused on protecting research participants and giving individuals access to scientific developments," said London, associate professor of philosophy and director of Carnegie Mellon's Center for the Advancement of Applied Ethics and Political Philosophy. "These are important issues. But ethical oversight needs to also ensure that decisions about launching human testing are based on a range of considerations that are not easily captured in the current focus."

"What is often overlooked," said Kimmelman, "is that allowing studies of poor scientific quality to proceed potentially undermines the entire scientific enterprise, because they undermine trust, consume scarce research resources, and weaken incentives for medical scientists to perform the best research they can."

"Clinical research is like a scientific bucket-brigade," London added, "where one group of scientists hands knowledge to the next, and they do a trial and hand their results to the next, and a problem with one link in the chain can derail a whole program."

To safeguard the advancement of medical research, the authors suggest that four key questions must be answered when researchers propose human studies of new therapies. They are:

  • Did animal experiments show reliable effects on disease?
  • Are the animal models similar enough to human beings that favorable results are to also occur in human trials?
  • To what extent are researchers justified in believing that observations in animals will hold up in human beings? and
  • Will clinical trials apply the exact conditions that were used in successful animal studies?

The authors suggest that there are instances when human trials are initiated despite unsatisfactory answers to these questions.

"Without critical feedback between preclinical and clinical investigators, oversight committees and sponsors, experiments lose focus and trials risk failure," Emborg notes. "Multilevel cooperation is needed for obtaining meaningful results in translational studies."

"The knowledge and interventions that science produces are valuable social goods," London said. "Everyone who cares about medical advance has an interest in preserving the integrity of the process that makes these goods possible."


Story Source:

The above story is based on materials provided by Carnegie Mellon University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Alex John London, Jonathan Kimmelman, and Marina Elena Emborg. Beyond Access vs. Protection in Trials of Innovative Therapies. Science, 2010; 328 (5980): 829-830 DOI: 10.1126/science.1189369

Cite This Page:

Carnegie Mellon University. "Ethics experts call for refocus of scientific review to ensure integrity of research process." ScienceDaily. ScienceDaily, 17 May 2010. <www.sciencedaily.com/releases/2010/05/100513143449.htm>.
Carnegie Mellon University. (2010, May 17). Ethics experts call for refocus of scientific review to ensure integrity of research process. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2010/05/100513143449.htm
Carnegie Mellon University. "Ethics experts call for refocus of scientific review to ensure integrity of research process." ScienceDaily. www.sciencedaily.com/releases/2010/05/100513143449.htm (accessed October 25, 2014).

Share This



More Science & Society News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Microsoft Riding High On Strong Surface, Cloud Performance

Microsoft Riding High On Strong Surface, Cloud Performance

Newsy (Oct. 24, 2014) Microsoft's Q3 earnings showed its tablets and cloud services are really hitting their stride. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Science & Society

Business & Industry

Education & Learning

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins